Clinical Trials Logo

Filter by:
NCT ID: NCT01684345 Terminated - Uveitis Clinical Trials

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

EYEGUARD™-A
Start date: August 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.

NCT ID: NCT01679951 Terminated - Clinical trials for Rheumatoid Arthritis

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Start date: October 31, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this dose range finding study is to assess the effectiveness, safety and tolerability of JNJ-38518168 at doses of 3, 10, and 30 mg/d compared with placebo in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy.

NCT ID: NCT01671033 Terminated - Panic Disorder Clinical Trials

Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring

Start date: February 2010
Phase: N/A
Study type: Interventional

From the scarce literature it showed that computer/internet-aided cognitive behavior therapy (CBT) was superior to waitlist and placebo assignment across outcome measures, and the effects of computer/internet-aided CBT were equal to therapist-delivered treatment across anxiety disorders. The aim of this study is to evidence the effectiveness of internet-based relaxation with biofeedback treatment for panic disorder.

NCT ID: NCT01670071 Terminated - Schizophrenia Clinical Trials

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

Start date: January 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effect of oral paliperidone extended-release and oral risperidone immediate-release on cognitive function, especially the category fluency of Cognitive Abilities Screening Instrument, Chinese version (CASI C-2.0), in patients with an established diagnosis of schizophrenia.

NCT ID: NCT01658358 Terminated - Clinical trials for Metastatic Breast Cancer

ErbB2 Positive Metastatic Breast Cancer

Start date: July 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Objectives: Phase I part - Primary Objective: To determine the recommended dose of the combination of lapatinib with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive metastatic breast cancer. - Secondary Objectives:To define the safety profile; To observe the response rate and progression free survival Phase II part - Primary Objective :To determined the objective response rate of the combination of lapatinib with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive metastatic breast cancer. - Secondary Objectives:To define the safety profile; To determined the progression free survival

NCT ID: NCT01654406 Terminated - Cesarian Scar Clinical Trials

Fractional CO2 Laser in the Treatment for Cesarian Scar

Start date: July 2012
Phase: N/A
Study type: Interventional

Fractional CO2 laser can improve the Cesarian scar

NCT ID: NCT01650805 Terminated - Clinical trials for Chronic Myeloid Leukemia

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Start date: June 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

NCT ID: NCT01648101 Terminated - Epilepsy Clinical Trials

Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

Start date: August 29, 2012
Phase: Phase 3
Study type: Interventional

The immediate release (IR) formulation of retigabine has been shown to be superior to placebo as adjunctive therapy in 3 adequate and well-controlled studies in subjects with drug-resistant partial-onset seizures (POS) who had previously failed to respond to two or more antiepileptic drugs (AEDs) and were still having seizures despite current treatment with 1, 2, or 3 AEDs. However, of 1244 subjects randomly assigned to treatment in these 3 clinical studies, only 10 were Asian subjects and only 5 of these Asian subjects were randomly assigned to treatment with retigabine. Therefore, this Phase III study is being conducted to evaluate the efficacy, safety and tolerability, and health outcomes of retigabine, at doses of 900 mg/day and 600 mg/day, compared with placebo in adult Asian subjects with drug-resistant POS.

NCT ID: NCT01647542 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

GRAND-307
Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific adults with type 2 diabetes mellitus (T2DM).

NCT ID: NCT01646125 Terminated - Clinical trials for Advanced Non Small Cell Lung Cancer (NSCLC)

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Start date: November 23, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations. The primary purpose of this study was to compare the efficacy of AUY922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced NSCLC, whose tumors harbored EGFR activating mutations, and had developed resistance to EGFR TKI.